Navigation Links
Halt Medical, Inc. Receives FDA Clearance

LIVERMORE, Calif., June 15 /PRNewswire/ -- Halt Medical, Inc., today announced that the U.S. Food and Drug Administration (FDA) has cleared the Halt 2000GI™ Electrosurgical System for soft tissue ablation using radiofrequency energy.  "This clearance to market is a major milestone for our customers, employees and investors," said Russ DeLonzor, President and Chief Operating Officer. 

Radiofrequency Ablation (RFA) with the Halt System is a very precise, minimally invasive procedure where a slender probe is inserted into the target tumor under ultrasound guidance.  Once in position, the system delivers a specified amount of energy to the tissue.  The heat generated in the process destroys the tumor, allowing it to be absorbed by the body.  RFA therapy is rapidly becoming the treatment of choice among surgeons seeking minimally invasive solutions for relieving debilitating symptoms caused by a variety of diseases such as tumors of the liver, breast, prostate, bone, and kidneys.   

"The Halt System offers broad advantages over surgery to doctors, their patients, and the healthcare system," according to Gordon Epstein, MD, Chief Technology Officer.  "With traditional surgical interventions, layers of healthy tissue are cut through to gain access to the tumor.  This leads to complications, significant pain, and long recovery times.  With RFA, patients typically go home the same day and are back to work much sooner.  The direct and indirect savings to the healthcare system as we replace radical surgery with minimally invasive procedures like Halt RFA will be in the billions of dollars."   

Halt Medical was founded in 2005 by Jeffrey M. Cohen, Dr. Bruce B. Lee, and Ed Calesa with the goal of developing an RFA system optimized for the treatment of symptomatic uterine fibroids.  The Halt Fibroid System was recently approved for use in Europe, and is currently being studied for this indication in the U.S.  "Receiving clearance by the FDA to market our general use ablation system represents a significant step towards our goal of extending the benefits of RFA to the treatment of uterine fibroids in the U.S.," said Mr. Cohen. 

Information about the Halt Fibroid Study and a list of clinical sites in the U.S. may be found at, study number NCT00874029.

SOURCE Halt Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Apnex Medical, Inc. Names Chas McKhann President, Chief Executive Officer
2. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
3. TriReme Medical, Inc. Receives FDA 510K Clearance for Glider(TM) PTA Balloon Catheter
4. Chinas leading electronic systems design event to highlight next-generation medical, automotive and green power technologies
5. Solta Medical, Inc. Announces Fourth Quarter 2009 Results Release Date and Conference Call
6. Tenaxis Medical, Inc. Announces Completion of the Enrollment Phase of Their Pivotal Study
7. China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters
8. China Sky One Medical, Inc.s AMI Diagnostic Kit Recognized as a National Innovation Project by NDRC
9. Home Care of the Carolinas and Alliance Medical, Inc. Select Authentidates Inscrybe Healthcare to Improve Care Order Processing
10. Apnex Medical, Inc. Raises Additional $14 Million
11. China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  Hanger, Inc. (NYSE: ... restatement of the terms of its previously announced consent ... to its $200,000,000 aggregate principal amount 7⅛% Senior Notes ... (i) the consent fees payable pursuant to the Consent ... Notes and (iii) the expiration date of the Consent ...
(Date:11/30/2015)...  Precision Image Analysis Inc. (PIA), a leading ... a dramatic expansion of its capabilities as a ... ISO-9001:2008 certification for its Quality Management System, PIA ... and procedures. This expansion enables PIA to support ... Lab services include design and optimization of protocols, ...
(Date:11/30/2015)... and REHOVOT, Israel , Nov. 30, ... company focused on acquiring and developing innovative therapies for ... appointment of Keith A. Katkin as chairman ... J. Flesher , chief executive officer for OticPharma, Ltd.  ... organizations.  As chairman, he will be able to share ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... (ASI) as their exclusive channel partner for the Nutraceutical Specialties products into oral ... the US, effective immediately. , “We are pleased to announce our expanded ...
(Date:11/30/2015)... ... 2015 , ... Medicalis, a leading developer of enterprise-scale Imaging ... (RSNA) annual meeting, being held November 29 – December 3, 2015, that its ... company has completed installations for Integrated Delivery Network (IDN) customers such as WellSpan, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen Plastic ... surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, one ... Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global medical ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. and ... Mesh technology for soft tissue repair in the US via Insightra’s national direct ... surgical mesh intended to support and reinforce soft tissue for 6-9 months before ...
(Date:11/30/2015)... ... ... TransPack Volume 6 features 30 customizable transitions created exclusively for use within ... with blur & drop shadow options. Utilize the controls in the inspector window ... the next with TransPack's easily customizable styles. , TransPack Volume 6 features ...
Breaking Medicine News(10 mins):